Tirzepatide Explored for Alcohol Use Disorder and Liver Disease

Alcohol Use Disorder (AUD) often leads to severe health complications, including Metabolic Alcohol-associated Liver Disease (MetALD), a complex condition encompassing liver damage, cardiovascular issues, and obesity, which can be fatal. Current treatments for AUD and MetALD are limited, highlighting an urgent need for novel therapeutic strategies. This Phase 2 study aims to evaluate if tirzepatide, an approved weight management drug, can effectively reduce alcohol intake and improve liver health in individuals suffering from both AUD and MetALD.

As this is a recruiting Phase 2 study (NCT07046819), there are no published findings yet. However, the study aims to determine if tirzepatide, a dual GLP-1 and GIP receptor agonist, can significantly reduce alcohol consumption and improve markers of liver health in individuals with MetALD and AUD. Key primary endpoints will likely include changes in weekly alcohol intake, liver enzyme levels (e.g., ALT, AST), and markers of liver steatosis (fatty liver). The primary objective is to evaluate the efficacy and safety of tirzepatide in reducing alcohol consumption and improving metabolic parameters in this vulnerable patient population over 12 weeks. Secondary objectives will likely assess improvements in body weight, glycemic control, and overall quality of life, comparing the tirzepatide group against the placebo group.